MedPath

VYNDAQEL

VYNDAQEL

Approved
DIN Number

02495732

Drug Class

Human

Market Date

Apr 7, 2020

Company
HC

Pfizer Canada Ulc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02495732
AIG Number0162031001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
N07XX08 TAFAMIDIS
Product Specifications
Dosage FormCapsule
Route of AdministrationOral
AHFS Classification24:04.92
Health Canada Classification

ACTIVE INGREDIENTS (1)

TAFAMIDIS MEGLUMINEActive
Strength: 20 MG
Monograph: TAFAMIDIS MEGLUMINE

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.